Current and Emerging Therapies for Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a complex and progressive disease of the pulmonary vasculature that requires targeted medical management for symptom control and improved survival. Use of targeted treatments requires specialized training. In less than 2 decades, multiple targeted treatment options, including oral, inhaled, and infused therapies, have been introduced and many more therapeutic developments are in the pipeline. Agents under investigation include new medications that target established pathways as well as those that target recently identified underlying mechanisms of PAH. In the next few years, multiple agents are anticipated to receive approval and will further shape the evolving treatment domain of PAH.